My Treatment Approach: Optimizing Treatment for Chronic GVHD - Episode 9

Recent Updates: REACH3, ROCKstar, and RWD

,

Medical experts discuss the recent updates presented at ASH 2023 and TANDEM 2024.

EP. 1: Differentiating Acute and Chronic Graft-vs-Host Disease
EP. 2: Navigating Chronic GVHD: Phases of Pathophysiology and Best Practices in Patient Monitoring
EP. 3: Optimizing Chronic GVHD Therapy
EP. 4: Navigating Treatment Decisions in Chronic GVHD
EP. 5: Overview of Advanced Therapies in cGVHD
EP. 6: Overview of the ROCKstar Study
EP. 7: Considerations for Third-Line Treatment in Chronic GVHD
EP. 8: Clinical Scenario: Treatment Selection in the third line and beyond in cGVHD
Now Viewing
EP. 9: Recent Updates: REACH3, ROCKstar, and RWD
EP. 10: AGAVE-201: Axatilimab for cGVHD
EP. 11: Emerging Trends in Chronic GVHD: Promising Clinical Trials and the Future Treatment Landscape
EP. 12: Clinical Impact of Patient-Reported Outcomes in cGVHD
EP. 13: Multidisciplinary Approaches to GVHD

Video content above is prompted by the following:

  1. Briefly discuss recent updates presented at ASH 2023 and TANDEM 2024:
  • 3-year analysis of REACH3, ASH 2023
  • 3-year follow-up of the ROCKstar study, TANDEM 2024
  1. Brie fly discuss available real-world data (RWD) with ruxolitinib (Spałek A, et al. Pol Arch Intern Med. 2023) and ibrutinib (Chin KK, et al. Transplant Cell Ther. 2021;White J, et al. Transplant Cell Ther. 2023).